SCHEMBL6073793

SCHEMBL6073793

CNC(=O)Nc1nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2cc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 9/20 0.51
CCND1 P24385 8/20 0.51
CDK2 P24941 6/20 0.51
CCNA2 P20248 5/20 0.51
FGFR1 P11362 4/20 0.51
FGFR2 P21802 4/20 0.51
FGFR4 P22455 4/20 0.51
FGFR3 P22607 4/20 0.51
CCND3 P30281 3/20 0.51
CCND2 P30279 2/20 0.51
MAPK8 P45983 1/20 0.51
MAPK9 P45984 1/20 0.51
MAPK10 P53779 1/20 0.51
CCNA1 P78396 1/20 0.51
BRD4 O60885 2/20 0.49
SYK P43405 2/20 0.48
IGF1R P08069 1/20 0.47
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
PTK2 Q05397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073723 0.90 CDK4 (0.49) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073499 0.86 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073923 0.84 CCND3 (0.54) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL6073559 0.80 CDK4 (0.49) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073686 0.80 CDK4 (0.49) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073477 0.78 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073707 0.78 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073818 0.77 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073948 0.77 CDK4 (0.44) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073945 0.77 CDK4 (0.44) CDK4CCND1CDK2CCNA2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CDK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.